The 25-patient trial also showed improved joint mobility; Mirum plans to submit an application to extend use to ages 6 to ...
Ascletis Pharma submitted an investigational new drug application to the U.S. FDA for ASC39, an oral small-molecule amylin receptor agonist for obesity, and expects to begin a Phase 1 trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results